Search Results

You are looking at 121 - 130 of 221 items for :

  • Refine by Access: All x
Clear All
Full access

Response Monitoring, Tolerability, and Effectiveness of Imatinib Treatment for Chronic Myeloid Leukemia in a Retrospective Research Database

David D. Stenehjem, Frederick Albright, Kuan-Ling Kuo, Karina Raimundo, Hillevi Bauer, Paul J. Shami, Michael W. Deininger, Lei Chen, and Diana I. Brixner

myalgias, fatigue, fever, edema, and headache. Among patients experiencing an ADE, 10 (32%) had a dose reduction. The median time to dose reduction was 52 days, and the new median dose was 300 mg/d. A total of 6 patients (19%) discontinued imatinib because

Full access

The Role of Bridge Therapy Prior to Orthotopic Liver Transplantation

Meena A. Prasad and Laura M. Kulik

.4% vs 61.5%; P =.0493). 30 Table 2 Factors to Consider Before RFA Unfortunately, more than 50% of patients undergoing TACE develop symptoms of postembolization syndrome, consisting of abdominal pain, fever, nausea, and vomiting. In

Full access

Emerging Therapy for the Treatment of Mantle Cell Lymphoma

Saurabh Rajguru and Brad S. Kahl

). Toxicity was not insignificant, with 17% and 12% of patients hospitalized for grade 3 and 4 adverse events (AEs), respectively—mostly neutropenic fever. The 4-year PFS and OS rates were 73% and 81%, respectively. 10 An update after 6 years of follow

Full access

Treatment of Non–Small Cell Lung Cancer in the Older Patient

Apar Kishor Ganti, Mollie deShazo, Alva B. Weir III, and Arti Hurria

in patients aged 70 years or older showed higher toxicity (neutropenic fever, hemorrhage, nausea, anorexia, and hypertension) in the elderly patients who received bevacizumab. 53 Moreover, the addition of bevacizumab did not confer a survival

Full access

Multiple Successful Desensitizations to Brentuximab Vedotin: A Case Report and Literature Review

Michael D. DeVita, Andrew M. Evens, Steven T. Rosen, Paul A. Greenberger, and Adam M. Petrich

: anaphylaxis 15 minutes into cycle 2, a delayed reaction 1 day after completing cycle 3, and an episode of rigors, fever, tachycardia, and hypotension at completion of cycle 3. 20 The patient in the present case report received her first cycle of brentuximab

Full access

Quality Indicators in the Management of Bladder Cancer

Jeffrey S. Montgomery, David C. Miller, and Alon Z. Weizer

to 71% of patients experiencing urinary frequency, 67% cystitis, 25% fever, and 23% hematuria. Serious local and systemic infections from BCG occur and may require antituberculosis therapy and even hospitalization. Although the use of BCG should be

Full access

Maintenance Therapy With Tyrosine Kinase Inhibitors After Transplant in Patients With Chronic Myeloid Leukemia

Merav Bar and Jerald Radich

3.2 months, respectively. The most common side effects reported in the clinical trial include hypertension, rash, abdominal pain, fatigue, headache, dry skin, constipation, fever, joint pain, and nausea. Arterial thrombosis and liver toxicity were

Full access

NCCN Guidelines Insights: Antiemesis, Version 2.2017

Michael J. Berger, David S. Ettinger, Jonathan Aston, Sally Barbour, Jason Bergsbaken, Philip J. Bierman, Debra Brandt, Dawn E. Dolan, Georgiana Ellis, Eun Jeong Kim, Steve Kirkegaard, Dwight D. Kloth, Ruth Lagman, Dean Lim, Charles Loprinzi, Cynthia X. Ma, Victoria Maurer, Laura Boehnke Michaud, Lisle M. Nabell, Kim Noonan, Eric Roeland, Hope S. Rugo, Lee S. Schwartzberg, Bridget Scullion, John Timoney, Barbara Todaro, Susan G. Urba, Dorothy A. Shead, and Miranda Hughes

serious skin reaction (drug reaction with eosinophilia and systemic symptoms [DRESS]) (see prescribing information), but other symptoms include a fever with a rash and swollen lymph glands, or swelling in the face; patients with these symptoms should seek

Full access

A Practice-Based Evaluation of Distress Screening Protocol Adherence and Medical Service Utilization

Brad Zebrack, Karen Kayser, Deborah Bybee, Lynne Padgett, Laura Sundstrom, Chad Jobin, and Julianne Oktay

psychological…social, and/or spiritual nature that may interfere with the ability to cope effectively with cancer, its physical symptoms, and its treatment.” 7 Distress is not a diagnosable disorder. Like fever or high blood pressure, distress is an indicator

Full access

Healthcare Utilization and End-of-Life Outcomes in Patients Receiving CAR T-Cell Therapy

P. Connor Johnson, Caron Jacobson, Alisha Yi, Anna Saucier, Tejaswini M. Dhawale, Ashley Nelson, Mitchell W. Lavoie, Mathew J. Reynolds, Carlisle E.W. Topping, Matthew J. Frigault, and Areej El-Jawahri

determine reasons for hospital readmissions. 12 In the schema for our study, these reasons included symptoms, fever without a source, febrile neutropenia, confirmed infection, dehydration/electrolyte abnormalities, planned hospitalization